Skip to content

FP7H2020HORIZON

Institute of Cancer Research: the Royal Cancer Hospital LBG

Country
GBUnited Kingdom
Defence projects
0
Projects, all programmes
39
As coordinator
17
EU contribution (CORDIS)
EUR 13,381,671
Active
2008 to 2026

Projects

39 projects, newest first

Projects, newest first
ProjectProgrammeYearRoleEU contribution
B-REDiTxOptimising cancer therapy scheduling through personalised mechanistic models and reinforcement learningHORIZON2026CoordinatorEUR 260,348
EVOBREASTUncovering immunoediting strategies underlying malignant transformation in breast tissuesHORIZON2025CoordinatorEUR 260,348
MONALISAA SIOPEN pragmatic clinical trial to MOnitor NeuroblastomA relapse with LIquid biopsy Sensitive AnalysisHORIZON2024Associated partnerEUR 0
CANCEREVODeciphering and predicting the evolution of cancer cell populationsH20202019ParticipantEUR 749,696
EVOMETThe rise and fall of metastatic clones under immune attackH20202019CoordinatorEUR 224,934
COLOSSUSAdvancing a Precision Medicine Paradigm in metastatic Colorectal Cancer: Systems based patient stratification solutionsH20202018ParticipantEUR 295,456
CONTRAComputational ONcology TRaining AllianceH20202018ParticipantEUR 273,288
UCOMUltrasound Cavitation in Soft MaterialsH20202018ParticipantEUR 606,345
ITCC-P4ITCC Pediatric Preclinical POC Platform – Sofia ref.: 116064H20202017ParticipantEUR 646,750
DRIVEDriving next generation autophagy researchers towards translationH20202017ParticipantEUR 273,288
REDOXCYCLEThe molecular interface between cell cycle and redox regulationH20202016CoordinatorEUR 235,695
FORCEImaging the Force of CancerH20202016ParticipantEUR 631,701
B-CASTBreast CAncer STratification: understanding the determinants of risk and prognosis of molecular subtypesH20202015ParticipantEUR 383,306
Human Rpc5RNA Polymerase III Rpc4/Rpc5 subcomplex and Selenocysteine tRNA transcriptionH20202015CoordinatorEUR 183,455
EMCOP9CRLStructural basis of Cullin-RING ligase regulation by the COP9 signalosomeH20202015CoordinatorEUR 183,455
RESICT-PCStudying Resistance to Cancer Therapeutics in Prostate CancerH20202014CoordinatorEUR 231,283
BARCODEThe use of genetic profiling to guide prostate cancer targeted screening and cancer careFP72014CoordinatorEUR 2,499,123
CDELPCHD1 Deletion: Implications to Outcome and Treatment in Prostate CancerH20202014CoordinatorEUR 231,283
LIVERNCODETranscribed-Ultraconserved Regions as novel biomarkers and therapeutic targets in liver cancerFP72013CoordinatorEUR 93,481
DECIDEDecision-making within cells and differentiation entity therapiesFP72013ParticipantEUR 285,057

The country is the one the source records for the organisation’s registration (its PIC), and each profile says what it rests on. Where the record contradicts itself (the address in one country, the site name and the VAT number in another) we follow the two that agree: the Spanish research council CSIC is shown under Spain although its address is recorded in Italy. A body with sites in several countries is shown under the first of them in alphabetical order, and its profile lists the others. Beyond that we do not guess.

Where this comes from

EU contribution is the amount CORDIS's open data pays to the participant. For a participant with linked third parties it may include their share (the CORDIS page prints the net); an amount the data does not hold is left out, not counted as zero. EDF factsheets state none per participant, so EDF projects count as projects but add nothing to the amounts.

Organisation-level facts only: a name, a country, a role, an amount, a year. A participant is recognised by its PIC where the source gives one, otherwise by name; the page says which. How the data is built.

Names are as CORDIS and the EDF project factsheets publish them. We do not list an organisation whose name looks like a natural person’s. If this entry is you, or a business named after you, and you want it removed, write to the contact in the imprint; the privacy notice (sections 7 and 9) says how a request is handled.